RED-BLOOD-CELL GLUTATHIONE LEVELS BEFORE AND DURING TREATMENT WITH NEOADJUVANT CHEMOTHERAPY CISPLATIN 5-FLUOROURACIL IN PATIENTS WITH HEAD AND NECK SQUAMOUS-CELL CARCINOMA/
L. Massaadmassade et al., RED-BLOOD-CELL GLUTATHIONE LEVELS BEFORE AND DURING TREATMENT WITH NEOADJUVANT CHEMOTHERAPY CISPLATIN 5-FLUOROURACIL IN PATIENTS WITH HEAD AND NECK SQUAMOUS-CELL CARCINOMA/, Anticancer research, 18(1A), 1998, pp. 283-288
The purpose of this study was to find out whether the glutathione (GSH
), in red blood cells could predict the response to neoadjuvant chemot
herapy cisplatin/5-fluorouracil (CDDP/5-FU) in patients with head and
neck squamous cell carcinoma (HNSCC). Three courses of induction chemo
therapy with CDDP/5-FU were administered and followed by surgery and r
adiotherapy or radiotherapy alone, in 51 patients with HNSCC. GSH was
measured by spectrophotometry in red blood cell, before any treatment
(Sample I: SI), after each course of chemotherapy (S2, S3, S4). Our re
sults showed that GSH was the same at diagnosis in patients with compl
ete or partial response (OR) compared to those with stable or progress
ive disease (NR). With regard to evolution of the GSH during the 3 cou
rses of CT a significant difference was found between courses (S2: 5.0
6 +/- 0.35 vs S4 = 3.61 +/- 0.4 mu mol/g haemoglobin, p < 0.05). When
we separated our patients into OR and NR, a significant difference was
found over the 3 courses of chemotherapy for GSH content. Non respond
er patients showed decreased GSH content at the end of the treatment,
(S2: 5 +/- 0.5 vs S4: 2.2 +/- 0.4 mu mol/g haemoglobin, p < 0.05) whil
e OR were stable. In conclusion, red blood cell GSH seems to have no e
arly predictive value for chemoresponse to neoadjuvant chemotherapy CD
DP/5-FU in HNSCC.